These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. Jiménez-Jiménez FJ; Molina JA; Aguilar MV; Meseguer I; Mateos-Vega CJ; González-Muñoz MJ; de Bustos F; Martínez-Salio A; Ortí-Pareja M; Zurdo M; Martínez-Para MC J Neural Transm (Vienna); 1998; 105(4-5):497-505. PubMed ID: 9720977 [TBL] [Abstract][Full Text] [Related]
6. CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis. Oeckl P; Steinacker P; Lehnert S; Jesse S; Kretzschmar HA; Ludolph AC; Otto M; Ferger B PLoS One; 2012; 7(3):e32664. PubMed ID: 22396786 [TBL] [Abstract][Full Text] [Related]
7. CSF cyclic nucleotides and somatostatin in Parkinson's disease. Volicer L; Beal MF; Direnfeld LK; Marquis JK; Albert ML Neurology; 1986 Jan; 36(1):89-92. PubMed ID: 2867490 [TBL] [Abstract][Full Text] [Related]
8. Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa. Manyam BV Arch Neurol; 1982 Jul; 39(7):391-2. PubMed ID: 7103767 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group. Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid selenium and chromium levels in patients with Parkinson's disease. Aguilar MV; Jiménez-Jiménez FJ; Molina JA; Meseguer I; Mateos-Vega CJ; González-Muñoz MJ; de Bustos F; Gómez-Escalonilla C; Ort-Pareja M; Zurdo M; Martínez-Para MC J Neural Transm (Vienna); 1998; 105(10-12):1245-51. PubMed ID: 9928893 [TBL] [Abstract][Full Text] [Related]
11. Influence of the therapy with pergolide mesylate plus L-DOPA and with L-DOPA alone on serum cGMP level in PD patients. Chalimoniuk M; Stepień A Pol J Pharmacol; 2004; 56(5):647-50. PubMed ID: 15591656 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186 [TBL] [Abstract][Full Text] [Related]
13. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease. Cedarbaum JM; Olanow CW Neurology; 1991 Oct; 41(10):1567-70. PubMed ID: 1922797 [TBL] [Abstract][Full Text] [Related]
14. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease. Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061 [TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. van Dijk KD; Jongbloed W; Heijst JA; Teunissen CE; Groenewegen HJ; Berendse HW; van de Berg WD; Veerhuis R Parkinsonism Relat Disord; 2013 Dec; 19(12):1079-83. PubMed ID: 23932065 [TBL] [Abstract][Full Text] [Related]
17. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Pisani V; Moschella V; Bari M; Fezza F; Galati S; Bernardi G; Stanzione P; Pisani A; Maccarrone M Mov Disord; 2010 May; 25(7):920-4. PubMed ID: 20461809 [TBL] [Abstract][Full Text] [Related]
18. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Olanow CW; Gauger LL; Cedarbaum JM Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185 [TBL] [Abstract][Full Text] [Related]